AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17996208 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB 0.02%
Number of subjects: 55
Study 17996208 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.02%
Number of subjects: 55
Study 16729916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide at 2000 mg in patients with nonmetastatic androgen-independent prostate cancer
Number of subjects: 0
Study 16729916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide at 500 mg or 2000 mg, intravenously twice weekly in patients with metastatic prostate cancer
Number of subjects: 0
Study 12588933 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 30
Study 12588933 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg reboxetine
Number of subjects: 30
Study 12588933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10986311 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARDs and/or corticosteroids
Number of subjects: 90
Study 8776365 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 1 week
Number of subjects: 161
Study 8776365 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 2 weeks
Number of subjects: 161
Study 8776365 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 4 weeks
Number of subjects: 161
Study 1594740 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program focused on health care professionals' use of basic communication skills, including a self-study instructional text and a 20-minute companion video.
Number of subjects: 0
Study 3972526 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 40
Study 3972526 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 40
Study 30388597 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 22
Study 30388597 — intervention group
Group type: COMPARATOR
Intervention: Obese controls (Ctr)
Number of subjects: 22
Study 29734817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin cement mantle group (n = 16)
Number of subjects: 30
Study 29734817 — intervention group
Group type: COMPARATOR
Intervention: Thick cement mantle group (n = 14)
Number of subjects: 30
Study 26847421 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Density (BD) information
Number of subjects: 138
Study 26847421 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging technology information
Number of subjects: 138
Study 26847421 — intervention group
Group type: EXPERIMENTAL
Intervention: BD information and imaging technology information (combined)
Number of subjects: 138
Study 25370394 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia (TA)
Number of subjects: 1000
Study 25370394 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar Anesthesia (PA)
Number of subjects: 1000
Study 23165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 140
Study 23165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 140
Study 23165810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 140
Study 23165810 — intervention group
Group type: COMPARATOR
Intervention: NaCl solution (Placebo)
Number of subjects: 140
Study 20388445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 61
Study 20388445 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (Control)
Number of subjects: 61
Study 18598095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1180 mg/day
Number of subjects: 64
Study 18598095 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioctic acid 600 mg/day
Number of subjects: 64
Study 15842525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1 g orally
Number of subjects: 8
Study 15842525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12160589 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG instillations alone
Number of subjects: 205
Study 12160589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating instillations of interferon‐alpha and BCG monthly for up to 1 year
Number of subjects: 205
Study 12160589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) instillations
Number of subjects: 205
Study 12160589 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 205
Study 10574555 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast condition
Number of subjects: 0
Study 10574555 — intervention group
Group type: COMPARATOR
Intervention: Low contrast condition
Number of subjects: 0
Study 7600834 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave warming of packed RBCs
Number of subjects: 24
Study 7600834 — intervention group
Group type: EXPERIMENTAL
Intervention: Countercurrent water bath warming of packed RBCs
Number of subjects: 24
Study 7600834 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave heating cartridge
Number of subjects: 24
Study 7600834 — intervention group
Group type: EXPERIMENTAL
Intervention: Countercurrent heat exchanger
Number of subjects: 24
Study 7600834 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line microwave device
Number of subjects: 24
Study 7600834 — intervention group
Group type: COMPARATOR
Intervention: Countercurrent water bath warming
Number of subjects: 24
Study 2223346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ohmeda 3700
Number of subjects: 0
Study 2223346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor N100
Number of subjects: 0
Study 2223346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor N200
Number of subjects: 0
Study 2223346 — intervention group
Group type: EXPERIMENTAL
Intervention: Datex Oscar
Number of subjects: 0
Study 2223346 — intervention group
Group type: COMPARATOR
Intervention: Venous obstruction and cold-induced peripheral vasoconstriction
Number of subjects: 0
Study 663698 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 263
Study 663698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 263
Study 31707329 — intervention group
Group type: EXPERIMENTAL
Intervention: Eastern European participants
Number of subjects: 1591
Study 31707329 — intervention group
Group type: COMPARATOR
Intervention: North American participants
Number of subjects: 1591
Study 27334464 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-focused HIV intervention program (27 couples) with 3 counseling sessions: 2 couples-focused sessions and 1 individual-focused session
Number of subjects: 112
Study 27334464 — intervention group
Group type: COMPARATOR
Intervention: General HIV prevention information session (29 couples)
Number of subjects: 112
Study 25220046 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction programme (group therapy with a 5-day educational intervention and five 2-hour follow-up visits)
Number of subjects: 124
Study 25042661 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 155
Study 25042661 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 155
Study 25042661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive CoA
Number of subjects: 155
Study 22971492 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal colostomy without damaging the muscle layer of the abdominal wall
Number of subjects: 128
Study 22971492 — intervention group
Group type: COMPARATOR
Intervention: Conventional colostomy
Number of subjects: 128
Study 19236549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-pot test product (fermented milk containing Bifidobacterium lactis DN-173010)
Number of subjects: 371
Study 19236549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-pot test product (fermented milk containing Bifidobacterium lactis DN-173010)
Number of subjects: 371
Study 19236549 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 371
Study 17870161 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-assisted case management
Number of subjects: 80
Study 17870161 — intervention group
Group type: COMPARATOR
Intervention: Case management as usual
Number of subjects: 80
Study 15081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) administered orally
Number of subjects: 3
Study 15081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) with particle size: 500-1000 microm
Number of subjects: 3
Study 15081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB) mixed with hydroxypropylmethylcellulose (HPMC)
Number of subjects: 3
Study 15081141 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-containing microballoons (MB)
Number of subjects: 3
Study 12171452 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement containing 1,000 mg supplemental calcium as calcium citrate malate (n=7)
Number of subjects: 16
Study 12171452 — intervention group
Group type: COMPARATOR
Intervention: Placebo of methylcellulose (n=9)
Number of subjects: 16
Study 9255524 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 111
Study 9255524 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 111
Study 8105778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment with cognitive therapy followed by exposure in vivo
Number of subjects: 73
Study 8105778 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 73
Study 8105778 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (cognitive-behavioral treatment)
Number of subjects: 73
Study 8105778 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list period (control)
Number of subjects: 73
Study 8105778 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 73
Study 3802928 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.2, 0.3, and 0.4 mg/kg body weight, followed by infusion of 2, 3, and 4 micrograms/kg/min)
Number of subjects: 12
Study 3802928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31695323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 µg/kg/h)
Number of subjects: 557
Study 31695323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 557
Study 31695323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 557
Study 29752923 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based contraceptive education
Number of subjects: 240
Study 29752923 — intervention group
Group type: COMPARATOR
Intervention: Conversational counseling
Number of subjects: 240
Study 29752923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (video and conversational)
Number of subjects: 240
Study 26611473 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to fludarabine and cyclophosphamide chemotherapy
Number of subjects: 370
Study 24691332 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the online training resource (Microsurgery Essentials)
Number of subjects: 17
Study 24691332 — intervention group
Group type: COMPARATOR
Intervention: No access to the online training resource
Number of subjects: 17
Study 24691332 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confidence in residents
Number of subjects: 17
Study 24691332 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience level of residents
Number of subjects: 17
Study 22390448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention care (IC)
Number of subjects: 312
Study 22390448 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 312
Study 20399952 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (200 mcg every 6 hours after initial 400 mcg vaginally)
Number of subjects: 64
Study 20399952 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (initial 400 mcg, then 200 mcg every 6 hours)
Number of subjects: 64
Study 17613583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium/vitamin D supplements and exercise/protein
Number of subjects: 24
Study 17613583 — intervention group
Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements
Number of subjects: 24
Study 16236107 — intervention group
Group type: COMPARATOR
Intervention: PCC (plasma-derived prothrombin concentrates)
Number of subjects: 12
Study 16236107 — intervention group
Group type: EXPERIMENTAL
Intervention: HPFIX (high purity FIX concentrate)
Number of subjects: 12
Study 12844328 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran
Number of subjects: 216
Study 12844328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ximelagatran
Number of subjects: 216
Study 12844328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dosage based on creatinine clearance or bodyweight
Number of subjects: 216
Study 11095442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment for 3-4 years
Number of subjects: 3658
Study 8720425 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg extended-release (ER)
Number of subjects: 30
Study 8720425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1304448 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg t.i.d.
Number of subjects: 24
Study 1304448 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 24
Study 3934968 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan/prednisone
Number of subjects: 101
Study 3934968 — intervention group
Group type: COMPARATOR
Intervention: colchicine
Number of subjects: 101
Study 3934968 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan/prednisone (only regimen)
Number of subjects: 101
Study 3934968 — intervention group
Group type: COMPARATOR
Intervention: colchicine (only regimen)
Number of subjects: 101
Study 3113974 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing factor (hGRF-44 NH2) administered intravenously at doses of 2.5-80 micrograms, 80-320 micrograms, and 75-600 micrograms
Number of subjects: 0
Study 31219706 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 42 Gy/6 fractions (range 25 - 54 Gy/6#)
Number of subjects: 21
Study 31219706 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 21
Study 28350537 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Physical Activity (SPA)
Number of subjects: 439
Study 28350537 — intervention group
Group type: COMPARATOR
Intervention: Unstructured Physical Activity (USPA)
Number of subjects: 439
Study 26444882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple stimulation
Number of subjects: 390
Study 26444882 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine stimulation
Number of subjects: 390
Study 26444882 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study 22762307 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 42
Study 21574673 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious salience growth factors
Number of subjects: 667
Study 21574673 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious attendance growth factors
Number of subjects: 667
Study 21574673 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 667
Study 21574673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrill seeking
Number of subjects: 667
Study 21574673 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adolescent substance use
Number of subjects: 667
Study 19485591 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session exposure treatment
Number of subjects: 196
Study 19485591 — intervention group
Group type: EXPERIMENTAL
Intervention: Education support treatment
Number of subjects: 196
Study 19485591 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 196
Study 17229902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 43
Study 17229902 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 43
Study 17229902 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 43
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant/antiaggregating agents
Number of subjects: 0
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxerutin
Number of subjects: 0
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 0
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic/thrombolytic agents
Number of subjects: 0
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 0
Study 15590533 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management of RVO
Number of subjects: 0
Study 10939703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium sulphate 10% plus lidocaine 1%
Number of subjects: 12
Study 10939703 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1%
Number of subjects: 12
Study 9399311 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on speed of throwing
Number of subjects: 26
Study 9399311 — intervention group
Group type: COMPARATOR
Intervention: Feedback on accuracy of throwing
Number of subjects: 26
Study 8173688 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-Metoprolol combination tablet
Number of subjects: 186
Study 8173688 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 186
Study 8173688 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 186
Study 3766838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing follow-up services
Number of subjects: 0
Study 3766838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nursing follow-up)
Number of subjects: 0
Study 31634450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS over the left DLPFC
Number of subjects: 14
Study 31634450 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS over the left DLPFC
Number of subjects: 14
Study 30355865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurolab aqueous drainage implant (AADI)
Number of subjects: 38
Study 30355865 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 38
Study 27203715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147
Study 27203715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 24025111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 500 mg daily (or 400 mg daily by intravenous infusion) for 7 days
Number of subjects: 258
Study 24025111 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 258
Study 22858044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL and morphine 1.5mg (Group B+Mor)
Number of subjects: 200
Study 22858044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL and magnesium 500 mg (Group B+Mg)
Number of subjects: 200
Study 22858044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine 10 mL morphine 1.5mg and magnesium 500 mg (Group B+Mor+Mg)
Number of subjects: 200
Study 22858044 — intervention group
Group type: COMPARATOR
Intervention: 0.1% bupivacaine 10 mL (Group B)
Number of subjects: 200
Study 20181257 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive intraoperative intravenous fluid administration (Group A)
Number of subjects: 192
Study 20181257 — intervention group
Group type: COMPARATOR
Intervention: Liberal intraoperative intravenous fluid administration (Group B)
Number of subjects: 192
Study 18664153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 45
Study 18664153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 45
Study 18664153 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode (LED)
Number of subjects: 45
Study 16451383 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS rinse 1
Number of subjects: 3
Study 16451383 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS rinse 2
Number of subjects: 3
Study 16451383 — intervention group
Group type: COMPARATOR
Intervention: Positive control rinse
Number of subjects: 3
Study 16451383 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 3
Study 28555207 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant installation in fresh extraction sockets grafted with cortico‐cancellous heterologous bone and porcine derma (group A)
Number of subjects: 24
Study 28555207 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant installation 4 months after tooth extraction and socket preservation using the same materials (group B)
Number of subjects: 24
Study 28555207 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant installation (group A)
Number of subjects: 24
Study 28555207 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant installation (group B)
Number of subjects: 24
Study 10717755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus 5-days primaquine
Number of subjects: 350
Study 10717755 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 350
Study 10717755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus 14-days primaquine
Number of subjects: 350
Study 10717755 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 25 mg/kg and 14-days primaquine
Number of subjects: 350
Study 7745511 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 597
Study 7745511 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 597
Study 1971516 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 285
Study 1971516 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily
Number of subjects: 285
Study 7025876 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 20
Study 7025876 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 20